The Verdict
Lori Calvasina has returned -6.2% vs S&P -5.6% over matched windows (16% win rate across 22 picks).
The Report Card
Every pick at a glance. Green = beat S&P. Red = didn't.
Lori Calvasina's Stock Recommendations, Graded
- KGC · BUY · Mar 12, 2026
Kinross Gold Corporation
Return -18.4% vs S&P -2.6%
- ENB · BUY · Mar 12, 2026
Enbridge Inc.
Return -0.3% vs S&P -2.6%
- GPN · BUY · Feb 27, 2026
Global Payments
Return -10.4% vs S&P -5.5%
- BX · BUY · Feb 27, 2026
Blackstone Inc.
Return -2.6% vs S&P -5.5%
Lori Calvasina's Best and Worst Stock Picks
Best: SUN (+12.4%) · Worst: KGC (-18.4%).
Lori Calvasina's Full Track Record
| Action | Ticker | Date | Headline | Return | vs S&P |
|---|
| SELL | VALE | | VALE: Vale SA — SELL Mar 2026RBC Capital downgrades Vale SA (VALE) to a Hold | ✓ Correct | +2.2% |
| BUY | KGC | | KGC: Kinross Gold Corporation — BUY Mar 2026RBC Capital Upgrades Kinross Gold (KGC) with Raised Price Target | -18.4% | -15.8% |
| BUY | ENB | | ENB: Enbridge Inc. — BUY Mar 2026RBC Capital Maintains an Outperform Rating on Enbridge Inc. (ENB) | -0.3% | +2.3% |
| BUY | GPN | | GPN: Global Payments — BUY Feb 2026RBC Capital Raises its Price Target on Global Payments Inc. (GPN) to $97 and Maintains a Sector Perform Rating | -10.4% | -5.0% |
| BUY | BX | | BX: Blackstone Inc. — BUY Feb 2026RBC Capital Initiates Blackstone (BX) Coverage with $179 Target on Strong Growth Outlook | -2.6% | +2.9% |
| BUY | BIIB | | BIIB: Biogen Inc. — BUY Feb 2026Biogen (BIIB) Receives a Buy from RBC Capital | -5.4% | +0.0% |
| SELL | MIRM | | MIRM: Mirum Pharmaceuticals — SELL Feb 2026Mirum Pharmaceuticals stock falls on R&D spending outlook, RBC reiterates Outperform | ✗ Incorrect | -1.9% |
| BUY | MRK | | MRK: Merck — BUY Feb 2026RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects | -4.3% | +1.6% |
| BUY | NVDA | | NVDA: Nvidia — BUY Feb 2026RBC Capital reiterates Nvidia stock Outperform rating at $250 target | -6.6% | -0.7% |
| BUY | LLY | | LLY: Eli Lilly — BUY Feb 2026RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030 | -11.9% | -5.4% |
| BUY | ABBV | | ABBV: AbbVie — BUY Feb 2026RBC Capital Initiates Coverage on AbbVie (ABBV) with Outperform Rating | -9.6% | -3.2% |
| BUY | LOW | | LOW: Lowe's Companies — BUY Feb 2026RBC Capital Raises Lowe's (LOW) Price Outlook after Strong January Trends | -14.6% | -8.2% |
| BUY | CNNE | | CNNE: Cannae Holdings — BUY Feb 2026RBC Capital Maintains Cannae Holdings(CNNE.US) With Buy Rating | -14.6% | -8.2% |
| BUY | WELL | | WELL: Welltower — BUY Feb 2026Welltower (WELL) Receives a Buy from RBC Capital | -5.9% | +0.5% |
| BUY | BN | | BN: Brookfield Corporation — BUY Feb 2026Brookfield Corporation (BN) Gets a Buy from RBC Capital | -16.1% | -9.6% |
| BUY | CVE | | CVE: Cenovus Energy — BUY Feb 2026RBC Capital Increases Cenovus Energy (CVE) Target | +12.0% | +17.7% |
| BUY | IRM | | IRM: Iron Mountain — BUY Feb 2026RBC Capital Maintains Iron Mountain(IRM.US) With Buy Rating | -12.0% | -6.4% |
| BUY | DTG | | DTG: Daimler Truck Holding AG — BUY Feb 2026Daimler Truck Holding AG (DTG) Gets a Buy from RBC Capital | -4.7% | +0.3% |
| BUY | SUN | | SUN: Sunoco — BUY Feb 2026Sunoco (SUN) Retains its Buy Rating at RBC Capital | +12.4% | +18.5% |
| BUY | GEL | | GEL: Genesis Energy — BUY Feb 2026Genesis Energy (GEL) Earns Buy Rating from RBC Capital | +2.5% | +8.6% |
| BUY | INTU | | INTU: Intuit Inc. — BUY Feb 2026RBC Capital Remains a Buy on Intuit Inc. (INTU) | -6.5% | +0.3% |
FAQ
Is Lori Calvasina good at picking stocks?
Lori Calvasina has 22 scored picks with 16% win rate and -0.5% vs S&P.
What stocks does Lori Calvasina recommend?
INTU, SUN, GEL, DTG, CVE, IRM.
What date range does this track record cover?
Feb 01, 2026 to Mar 13, 2026.
Share Card
